The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Anturane     1,2-diphenyl-4-[2- (phenylsulfinyl)ethyl]py...

Synonyms: Anturan, sulfinpyrazone, Sulphinpyrazone, Nu-Sulfinpyrazone, Nu Sulfinpyrazone, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of sulfinpyrazone


High impact information on sulfinpyrazone


Chemical compound and disease context of sulfinpyrazone


Biological context of sulfinpyrazone


Anatomical context of sulfinpyrazone


Associations of sulfinpyrazone with other chemical compounds


Gene context of sulfinpyrazone


Analytical, diagnostic and therapeutic context of sulfinpyrazone


  1. More on sulfinpyrazone after myocardial infarction. Hood, W.B. N. Engl. J. Med. (1982) [Pubmed]
  2. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. Cairns, J.A., Gent, M., Singer, J., Finnie, K.J., Froggatt, G.M., Holder, D.A., Jablonsky, G., Kostuk, W.J., Melendez, L.J., Myers, M.G. N. Engl. J. Med. (1985) [Pubmed]
  3. Medical treatment for stroke prevention. Matchar, D.B., McCrory, D.C., Barnett, H.J., Feussner, J.R. Ann. Intern. Med. (1994) [Pubmed]
  4. Interactions of warfarin with drugs and food. Wells, P.S., Holbrook, A.M., Crowther, N.R., Hirsh, J. Ann. Intern. Med. (1994) [Pubmed]
  5. The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. Kaegi, A., Pineo, G.F., Shimizu, A., Trivedi, H., Hirsh, J., Gent, M. Circulation (1975) [Pubmed]
  6. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. Evers, R., Zaman, G.J., van Deemter, L., Jansen, H., Calafat, J., Oomen, L.C., Oude Elferink, R.P., Borst, P., Schinkel, A.H. J. Clin. Invest. (1996) [Pubmed]
  7. Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist. Dahinden, C., Fehr, J. J. Clin. Invest. (1980) [Pubmed]
  8. Sex difference in antithrombotic effect of sulphinpyrazone. Pay, G.F., Wallis, R.B., Zelaschi, D., Burley, D.M., Dalton, M., Giorgiades, E., Ginsburg, J. Lancet (1982) [Pubmed]
  9. Haemodynamic effects of sulphinpyrazone on exercise responses in normal subjects. Forfar, J.C., Russell, D.C., Oliver, M.F. Lancet (1980) [Pubmed]
  10. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Goldman, S., Copeland, J., Moritz, T., Henderson, W., Zadina, K., Ovitt, T., Doherty, J., Read, R., Chesler, E., Sako, Y. Circulation (1988) [Pubmed]
  11. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. O'Reilly, R.A. Circulation (1982) [Pubmed]
  12. Summary of design features: clinical trials of platelet-active drugs in cerebrovascular disease. Friedman, L.M. Circulation (1980) [Pubmed]
  13. Are agents affecting platelet functions clinically useful? Verstraete, M. Am. J. Med. (1976) [Pubmed]
  14. Prevention of postoperative deep vein thrombosis by a combination of subcutaneous heparin with subcutaneous dihydroergotamine or oral sulphinpyrazone. Veth, G., Meuwissen, O.J., van Houwelingen, H.C., Sixma, J.J. Thromb. Haemost. (1985) [Pubmed]
  15. Platelet and coagulation function in patients with abnormal cardiac valves treated with sulphinpyrazone. Ludlam, C.A., Allan, N., Blandford, R.B., Dowdle, R., Bentley, N.J., Bloom, A.L. Thromb. Haemost. (1981) [Pubmed]
  16. Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone. Cade, J.F., Doyle, D.J., Chesterman, C.N., Morgan, F.J., Rennie, G.C. Circulation (1982) [Pubmed]
  17. Interruption of tumor-associated platelet consumption with platelet enzyme inhibitors. Slichter, S.J., Weiden, P.L., O'Donnell, M.R., Storb, R. Blood (1982) [Pubmed]
  18. Preservation of platelets during extracorporeal circulation in sheep. A comparison between aspirin and sulfinpyrazone. Townsend, E.R., Duffin, J., Ali, M., McDonald, J.W., Thiesson, J.J., Masterson, J., Klement, P., Cooper, J.D. Circ. Res. (1981) [Pubmed]
  19. Pulmonary leukostasis and its relationship to pulmonary dysfunction in sheep and rabbits. Fountain, S.W., Martin, B.A., Musclow, C.E., Cooper, J.D. Circ. Res. (1980) [Pubmed]
  20. ATP-dependent transport of reduced glutathione on YCF1, the yeast orthologue of mammalian multidrug resistance associated proteins. Rebbeor, J.F., Connolly, G.C., Dumont, M.E., Ballatori, N. J. Biol. Chem. (1998) [Pubmed]
  21. Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Harker, L.A. Circulation (1986) [Pubmed]
  22. Platelet survival time in patients with hypoxemia and pulmonary hypertension. Steele, P., Ellis, J.H., Weily, H.S., Genton, E. Circulation (1977) [Pubmed]
  23. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Harker, L.A., Harlan, J.M., Ross, R. Circ. Res. (1983) [Pubmed]
  24. Abnormalities of urinary sediment and renal failure following sulfinpyrazone therapy. Braun, J. Arch. Intern. Med. (1976) [Pubmed]
  25. Clinical pharmacology of platelet cyclooxygenase inhibition. Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F., Davì, G., Forni, L. Circulation (1985) [Pubmed]
  26. Effects of clofibrate and sulfinpyrazone on platelet survival time in coronary artery disease. Steele, P., Battock, D., Genton, E. Circulation (1975) [Pubmed]
  27. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. Morrow, C.S., Smitherman, P.K., Diah, S.K., Schneider, E., Townsend, A.J. J. Biol. Chem. (1998) [Pubmed]
  28. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. Raggers, R.J., van Helvoort, A., Evers, R., van Meer, G. J. Cell. Sci. (1999) [Pubmed]
  29. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Pedersen, A.K., FitzGerald, G.A. Clin. Pharmacol. Ther. (1985) [Pubmed]
  30. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. Ito, K., Oleschuk, C.J., Westlake, C., Vasa, M.Z., Deeley, R.G., Cole, S.P. J. Biol. Chem. (2001) [Pubmed]
  31. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Depeille, P., Cuq, P., Passagne, I., Evrard, A., Vian, L. Br. J. Cancer (2005) [Pubmed]
  32. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Evers, R., de Haas, M., Sparidans, R., Beijnen, J., Wielinga, P.R., Lankelma, J., Borst, P. Br. J. Cancer (2000) [Pubmed]
  33. Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. Smeets, P.H., van Aubel, R.A., Wouterse, A.C., van den Heuvel, J.J., Russel, F.G. J. Am. Soc. Nephrol. (2004) [Pubmed]
  34. Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. Sautter, R.D., Koch, E.L., Myers, W.O., Ray, J.R., Mazza, J.J., Larson, D.E., Chen, H.M., Milbauer, J.P., Treuhaft, P.S., Plotka, E.D. JAMA (1983) [Pubmed]
  35. The effects of antithrombotic drugs in patients with left ventricular thrombi: assessment with indium-111 platelet imaging and two-dimensional echocardiography. Stratton, J.R., Ritchie, J.L. Circulation (1984) [Pubmed]
WikiGenes - Universities